Blood

Vol. 147, Issue 25 Issue 25 2026
21
Articles

Articles in this Issue

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

Lili Ren, Honghai Zhang, Olga Bobileva et al. Jun 18, 2026 pp. 3069-3085 10.1182/blood.2025030336

Abstract N7-methylguanosine (m7G), a prevalent modification in transfer RNAs (tRNAs), is primarily catalyzed by the methyltransferase METTL1. Although growing evidence supports a r...

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial

Moritz Fürstenau, Carsten U. Niemann, Sandra Robrecht et al. Jun 18, 2026 pp. 3025-3038 10.1182/blood.2025032160

Abstract Fixed-duration venetoclax combinations have become a standard first-line treatment in chronic lymphocytic leukemia (CLL). The phase 3 CLL13/GAIA trial assesses 3 time-limi...

Pathogenic role of serpin B3-positive neutrophils in reinforcing thrombus stiffening during ischemic stroke

Jiankun Zang, Aijun Lu, Bing Yang et al. Jun 18, 2026 pp. 3086-3101 10.1182/blood.2025029516

Abstract The contribution of immune cells to thrombus architecture and mechanical properties in acute ischemic stroke (AIS) remains poorly understood. Using 3-dimensional imaging a...

Signal AML stem cells to home: written and sent by METTL1

Diu T. T. Nguyen Jun 18, 2026 pp. 2994-2996 10.1182/blood.2026033731

Immune-mediated side effects of cancer immunotherapies

Lukas M. Braun, Jarushka Naidoo, Robert Zeiser Jun 18, 2026 pp. 3001-3024 10.1182/blood.2025030059

Abstract Immunotherapies, such as allogeneic hematopoietic cell transplantation and infusion of chimeric antigen receptor (CAR) T cells have significantly extended our therapeutic...

The clot stiffens: neutrophil serpin B3 in ischemic stroke

Maité Mulkers, Rainer Kaiser Jun 18, 2026 pp. 2996-2998 10.1182/blood.2026033710

Gonadal function and fertility after Hodgkin lymphoma treatment with nivolumab-AVD in the phase 2 GHSG NIVAHL trial

Anne Sophie Robertz, Ina Bühnen, Julia Meissner et al. Jun 18, 2026 pp. 3118-3121 10.1182/blood.2025031809

Abstract In 82 patients with classic Hodgkin lymphoma, stable gonadal hormone levels were observed up to 24 months after nivolumab in combination with doxorubicin, vinblastine, and...

Frontline CLL: lessons from the final analysis of CLL13-GAIA

Mathias Castonguay, Mary Ann Anderson Jun 18, 2026 pp. 2989-2990 10.1182/blood.2026033777

Multinucleated plasma cells and IgG λ myeloma in a patient with TEMPI syndrome and renal cell carcinoma

Adam Lyle, Peng Li Jun 18, 2026 pp. 3122-3122 10.1182/blood.2025032992

The prevalence and clinical significance of clonal monocytosis

William G. Dunn, Michael C. Sachs, Matteo Maggi et al. Jun 18, 2026 pp. 3039-3050 10.1182/blood.2025031883

Abstract The terms clonal monocytosis of undetermined significance (CMUS) and clonal cytopenia and monocytosis of undetermined significance (CCMUS) were introduced by the Internati...

The RELEVANCE of long-term follow-up in follicular lymphoma

Janlyn Falconer Jun 18, 2026 pp. 2993-2994 10.1182/blood.2026034016

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis

Nicolas Gower, Pierre Feugier, Jason Westin et al. Jun 18, 2026 pp. 3061-3068 10.1182/blood.2026033126

Abstract In the multinational, phase 3 RELEVANCE trial, 1030 patients with previously untreated follicular lymphoma were randomized to receive rituximab + lenalidomide (R2; n = 513...

Monocytes matter: prognostic impact in clonal hematopoiesis

Robert P. Hasserjian Jun 18, 2026 pp. 2990-2992 10.1182/blood.2026033840

Less is more in primary cutaneous indolent B-cell lymphoma

Lena Specht Jun 18, 2026 pp. 2992-2993 10.1182/blood.2026033604

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. <i>Blood</i> . 2026;147(18):2041-2052.

Jun 18, 2026 pp. 3123-3123 10.1182/blood.2026034829

Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis

Michael Oertel, Bouthaina Dabaja, Dennis Görlich et al. Jun 18, 2026 pp. 3051-3060 10.1182/blood.2025032050

Abstract Radiotherapy is an established treatment for low-grade primary cutaneous B-cell lymphoma. Recommendations on its use differ internationally, which prompted our group to co...

Ticks and transfusions: a potentially fatal mix!

Sheryl van Nunen Jun 18, 2026 pp. 2999-3000 10.1182/blood.2026033810

Platelets under pressure: a sticky outside-in problem

Gowtham K. Annarapu, Sruti Shiva Jun 18, 2026 pp. 2998-2999 10.1182/blood.2026034069

The 10-year RELEVANCE trial analysis

Jun 18, 2026 pp. 3124-3124 10.1182/blood.2026034593

A novel G13-RAPGEF2-RAP1 signaling pathway critical for platelet adhesion and aggregation

David S. Paul, David J. Rocco, Emily G. Clark et al. Jun 18, 2026 pp. 3102-3112 10.1182/blood.2025032282

Abstract Hemostasis and thrombosis are strongly dependent on the unique ability of platelets to rapidly activate integrin receptors and to firmly adhere to sites of injury under sh...

Severe allergic transfusion reactions to group B/AB plasma or platelets in group O recipients are linked to α-Gal sensitization

Luc De Chaisemartin, Virginie de la Taille, Pascale Nicaise-Roland et al. Jun 18, 2026 pp. 3113-3117 10.1182/blood.2025032045

Abstract Allergic transfusion reactions (ATR) are potentially lethal adverse events that occur in ∼0.3% to 6% of plasma or platelet transfusions. The main mechanism described is an...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page